BOTULIFT®
Accuracy, predictability and efficacy in neuromodulation with botulinum toxin type A¹.
BOTULIFT® is a botulinum toxin type A with a safety profile, predictability and efficacy proven by scientific studies¹². Its high purity formulation allows precise control of muscle contraction, predictable onset of action and consistent clinical duration, promoting natural results and high patient satisfaction²³.
Product features
Controlled precision¹
Selective action on the target muscles, with clinical predictability and preservation of the naturalness of expressions.
Proven safety profile¹
Developed to rigorous standards of quality and purity.
Safety and Quality²
Predictable and consistent results.
Up to 72 hours to take effect³
Progressive onset of action, respecting muscle physiology.
Lasts 3 to 5 months²
Prolonged maintenance of clinical results.
High patient satisfaction³
Natural and harmonious results.
After reconstitution
Stability under refrigeration (2 °C to 8 °C) for up to 7 days¹.
Effect durability¹
With onset of action within 72 hours and clinical peak between 5 and 7 days, BOTULIFT® maintains its effect for 3 to 5 months, offering therapeutic predictability and safety to the professional throughout the treatment cycle.
Simple, standardized reconstitution¹
Step by step developed for maximum safety and clinical consistency, facilitating the professional's routine and guaranteeing precise dosage control.
BOTULIFT® 100U
Neuromodulator precision for focal treatments and fine adjustments
BOTULIFT® 100U is indicated for facial neuromodulation procedures that require high precision and dose control. Ideal for localized treatments and fine adjustments, it provides predictable muscle relaxation, with a progressive onset of action and natural results²³.
Benefits
- Precise control of muscle contraction in specific areas².
- Preserving the naturalness of facial expressions³.
- High clinical predictability in one-off treatments¹.
Indications
- Dynamic wrinkles of the upper third of the face².
- Localized neuromodulation in small areas³
- Fine adjustments in personalized aesthetic protocols¹.
Differentials
- High purity and stability of botulinum toxin¹.
- Controlled diffusion, reducing unwanted dispersion².
- Safety profile approved by ANVISA¹.
Additional content
Vial with 100 units: indicated for high-precision facial neuromodulation, allowing treatment customization, strict dosage control and clinical predictability¹².
BOTULIFT® 150U
Clinical versatility for complete facial neuromodulation.
BOTULIFT® 150U was developed for more comprehensive facial neuromodulation protocols, offering a balance between performance, control and predictability. Suitable for complete treatments, it maintains consistent efficacy and natural results over time²³.
Benefits
- Efficient coverage of multiple muscle groups².
- Consistent results with a high patient satisfaction rate³.
- Clinical duration of 3 to 5 months¹².
Indications
- Dynamic wrinkles of the upper and middle third².
- Complete facial neuromodulation protocols¹.
- Prevention and smoothing of the signs of aging³.
Differentials
- Ideal balance between available volume and clinical versatility¹.
- Homogeneous diffusion with predictable onset of action².
- Stability after reconstitution under refrigeration for up to 7 days¹.
Additional content
Vial with 150 units: versatile solution for complete facial neuromodulation treatments, providing clinical efficiency, predictability of results and optimization of medical practice¹²³.
BOTULIFT® 200U
High-performance neuromodulators for extensive treatments.
BOTULIFT® 200U is indicated for more comprehensive neuromodulation procedures, offering high yield and consistent performance. Ideal for treatments involving multiple areas, it combines clinical efficiency, safety and predictability in aesthetic and therapeutic protocols¹².
Benefits
- High performance for extensive treatments¹.
- Consistent performance even in multiple areas².
- Maintenance of clinical effect for up to 3-5 months¹².
Indications
- Complete facial neuromodulation².
- Treatments of multiple regions in a single protocol¹.
- Aesthetic and therapeutic protocols with the highest clinical demand³.
Differentials
- Stability and purity guarantee clinical consistency¹.
- Controlled diffusion even in larger volumes².
- Optimization of time and resources in the clinical routine³.
Additional content
200-unit vial: indicated for high-demand neuromodulation procedures, offering high performance, proven safety and clinical predictability supported by scientific evidence¹².
Technology and Quality
Technology developed at Korea, with purity and stability profile demonstrated in studies, ensuring high standards of quality, safety and clinical predictability.
Bibliographical references
Botulift® (botulinum toxin A). Product leaflet approved by ANVISA - Letter to Health Professionals: Safety and efficacy information on botulinum toxin type A - Botulift, 2024. Available at: https://www.gov.br/anvisa
Han KH, Kim W-S, Lee Y, Kim JH, et al. “Efficacy and safety of a newly developed botulinum toxin A (HEA-Pot) in patients with moderate-to-severe glabellar lines: A randomized, double-blind, active-controlled, multi-center, phase III study.” Toxins, 2025.
Han HS, Lee Y, Kim BJ, et al. “Long-term safety and sustained efficacy of HEA-Pot for glabellar lines: Results from a 52-week open-label extension study.” Dermatologic Surgery, 2024.
Beer KR. “Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar wrinkles.” Dermatologic Surgery, 2006; 32(2): 189–197.
Dressler D. “Pharmacology of botulinum toxin A products and interchangeability: A review of the therapeutic, biological, and pharmacological evidence.” Toxicon, 2014.
Lee HJ, Seo KH, Park YJ, et al. “Comparative pharmacodynamics study of three different botulinum toxin type A preparations: Evaluation of diffusion, onset, and potency.” Dermatologic Surgery, 2020.
Contact us
We'd love to hear from you